Margin maintenance at 30%+
Management expects current EBITDA margin levels (30.5%) to be maintained for rest of FY24 with further improvement possible from Curatio synergies and operating leverage.
TORNTPHARM / guidance tracker
Keep management guidance in view.
Torrent Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
75-100bps annual margin improvement
Branded segment (72-73% of revenues) benefits from annual price increases and operating leverage. With no negatives from generics, 75-100 basis points year-on-year improvement is typical.
Brazil H2 pickup with ~6 launches
Brazil traditionally has stronger H2 with Q3/Q4 seeing larger proportions due to pre-Christmas sales and April price changes. 6 total branded launches planned in CNS and cardio with 5 remaining after Q1 launch.
Germany Q4 recovery
New tender wins from Q1 will start contributing in Q4 FY24 given 6-month lag between tender wins and sales commencement. Q2 and Q3 expected stable before Q4 uptick.
India Business Growth: 13-15% for FY25
Management expects low-teen to 15% growth for India business going forward, with Q1 at 15% serving as the higher end. Growth driven by chronic therapies, new launches including Vonoprazan/Kabvie, and improved field force productivity.
Brazil Growth: 12-13% underlying rate
Based on IQVIA MAT and quarterly data showing 12% growth for Torrent, management guides for 12-13% constant currency growth in Brazil over the medium term. Q1 was impacted by floods but should normalize from Q2.
U.S. FDA Resolution: October 2024
Response to FDA Form 483 (5 observations) has been submitted; management expects feedback by October with high likelihood of VAI/NAI classification for Indrad facility.
Tax Rate: 30% for FY25, 26-27% from FY27
Effective tax rate for FY25 is ~30%, same as Q1. From next fiscal year, transition to new tax regime in India should bring overall tax down to 26-27%.
Minimum 32.9% EBITDA margin to sustain for FY2026
Management expects the adjusted operating margin of 32.9% (excluding INR 15 crore one-off acquisition expense) to be the floor for all remaining quarters, with potential upside from operating leverage.
Target 6,900-7,000 MRs by FY26 year-end
India field force expansion continues with ~200 MR additions per quarter, focusing on chronic segment expansion and new division coverage.
~10 product launches planned in U.S. for FY2026
First quarter saw 4-5 launches including esomeprazole granules and sacubitril; another 5-6 launches expected in remaining quarters to drive revenue growth.
Brazil: 8-10 product launches per year
Three divisions in Brazil each targeting 2-3 launches annually, supported by 62 molecules in approval queue with varying timelines.
U.S. revenue run rate of $30-35 million per quarter
Sequential stabilization expected as new product approvals from Dahej and Indrad plants begin flowing through. Dahej EIR received enabling new launches. Price erosion running mid-single to high-single digit annually.
Gross margin sustainably at 75%
Portfolio optimization in U.S. and cost efficiencies are driving structural improvement. No one-off impacts in Q2. No immediate headroom for further expansion in next two quarters.
India market growth at 7-8%, Torrent base at 12%
AIOCD 4% market growth is understated; real market is ~7-8%. Acute therapies reviving; gastro demand improving sequentially. Torrent delta vs. market expected to remain similar for rest of FY24 and FY25.
Net debt/EBITDA below 1x by March 2024
Currently at 1.16x leverage. Cash generation from strong EBITDA (31% margin) and working capital management will reduce debt. March 2024 target achievable.
EBITDA Margin Expansion: 50-100bps annually for next 3 years
Driven by operating leverage from branded businesses and reduced investment pace. Germany has tender visibility for 2 years; U.S. slow ramp-up will be margin positive.
U.S. Business: Stable to slightly increasing revenues over 2-3 years
Expecting slow ramp-up as most ANDAs are old due to prior plant issues. Aim to make U.S. profitable (pre-R&D break-even currently) within 3 years.
CapEx: INR 250-300 crore annually
Torrent indicated annual CapEx guidance for the next 2-3 years. Debt repayment of INR 500-600 crore expected in H2 FY25.
Brazil: Double-digit top-line growth, H2 traditionally stronger
Management expects Brazil to continue growing faster than market (8-9% IPM) with 1-2 product launches per division annually and 5-10 generics launches per year.
India field force expansion to 7,000 reps by FY26 year-end
Currently at 6,800 MRs with continued expansion planned; approximately half for existing chronic/sub-chronic division expansion and half for new therapy area entry.
Germany supply disruption normalization by Q4 FY26
Third-party supplier disruption expected to continue through Q3 but should normalize from Q4 onwards if supplier resolution progresses as anticipated.
Annual CapEx of INR 250-300 crore over next 3 years
H1 CapEx was ~INR 200 crore with full-year FY26 guidance of ~INR 300 crore; maintain run-rate of INR 250-300 crore annually for the next three years.
New therapy division entry in India by Q4 FY26
Planning to enter one new therapeutic area this quarter with announcement expected by Q4; field force allocation for this division being built into the 7,000 rep target.
31.8% EBITDA margin as new sustainable base
Management explicitly stated current margin levels represent the new floor with operating leverage and price increases providing annual expansion. Target is 50-100bps improvement annually.
7-8 U.S. product launches in Q1 FY25
New product launches will begin from Q1 next fiscal year to fuel growth. Management expects the U.S. business trajectory to move upward with improved scale.
R&D spend to be 5-5.5% in FY25, 5.5-6% in FY26
Increased R&D investment planned as U.S. launches commence and pipeline develops for future growth.
Germany incremental revenue from Q2 FY25
New tenders won during Q3 will start delivering incremental sales from Q2 of next fiscal year, with management guiding upward revenue trend.
Margin Improvement: 50-100 bps annually
Management expects EBITDA margins to expand 50-100 basis points per year going forward. FY25 full-year margin expected at ~32.5% vs 31.4% in FY24, implying ~110bps improvement this year.
Net Cash Target: H1 FY27
Company expects to become net cash by first half of FY2027 as debt repayments continue. Interest expenses will decline quarter-on-quarter as repayments progress.
GLP-1 Launch: Day-One Presence in India and Brazil
Management confirmed intent to launch GLP-1 products on day one of market opening in both India (March 2026) and Brazil (January 2026). For injectables, manufacturing will be partnered; oral GLP-1 will be in-house.
Brazil Price Revision: Double-Digit Expected April 2026
Annual government-mandated price revisions in Brazil expected to be closer to double-digit (vs mid-single digit in last 3-4 years), providing price compensation starting April 2026.
JB margin improvement to 32-33%
JB's current 28-29% EBITDA margin has significant scope to converge toward Torrent's 32.5-33% base business margin, with synergy realization starting Q4 FY26.
US sales targeting $200M+ annual run rate
Management expressed optimism that current US business ($144M annualized) can grow to cross $200M per year by FY27, driven by 5-7 new launches annually and facility clearances.
India field force expansion to 7,500
Current field force of 6,900 to increase to just over 7,000 by FY26 year-end and approximately 7,500 by end of FY27, enabling continued market share gains.
Net debt trajectory to 0.6x EBITDA by FY29
Net debt/EBITDA guided at 1.1x in FY28 and 0.6x in FY29 as integration progresses and cash generation accelerates post-JB consolidation.
India growth to outperform IPM by 2-3%
With IPM growth expected at ~9%, management expects India business to grow at 11-12% in FY25, driven by chronic therapy expansion, new launches, and field force productivity improvements.
Brazil growth target of 14-15% in FY25
Management expects Brazil to continue its strong momentum with ~15% constant currency growth, supported by new launches, volume growth, and price increases of ~4.5% announced in April.
Germany growth at high single digit
With tender wins flowing from Q2 FY25 and 10-15 product launches planned, Germany is expected to maintain high single-digit growth trajectory.
50-100bps EBITDA margin expansion in FY25
Margin improvement expected from price increases across branded generic segments, operating leverage in Germany and Brazil, and positive US contribution. Excludes planned incremental consumer health investments.
India MR Expansion to 6,800-6,900
Adding 400-500 MRs by FY26 year-end, primarily in chronic therapies, to improve territorial reach and new launch performance in expanded divisions.
Brazil Double-Digit Constant Currency Growth
Expecting 10-12% constant currency growth in FY26, 2-3 percentage points ahead of estimated 9% market growth rate.
R&D Spend Increasing to ~5.4%
R&D as percentage of sales expected to move from ~5% towards 5.4%, driven by complex products in India, Brazil, and U.S. ($5-10M per product vs $2M for oral solids).
U.S. Launches: 7-8 Products in Next 12 Months
Expecting 7-8 launches including Eslicarbazepine (20%+ market share achieved on day one), Esomeprazole granules, and Diclofenac sachets. Meaningful growth impact delayed to FY27.